StockData
Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. (STOK) stock

STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30173% above fair value
$26.69+0.28 (+1.06%)

Close on Nov 18, 2026Market cap $1.72BP/E –Yield –

Stoke Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Stoke Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$223.38M, down 654.5% year over year. For fiscal 2025 it was -$20.59M. The highest annual figure on record is -$12.78M in fiscal 2018.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$20.59M–
FY2024Dec 31, 2024-$101.37M–
FY2023Dec 31, 2023-$114.77M–
FY2022Dec 31, 2022-$104.36M–
FY2021Dec 31, 2021-$86.07M–
FY2020Dec 31, 2020-$53.04M–
FY2019Dec 31, 2019-$35.68M–
FY2018Dec 31, 2018-$12.78M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$65.43M–
Q1 FY2026Mar 31, 2026-$53.42M-148.0%
Q4 FY2025Dec 31, 2025-$61.44M–
Q3 FY2025Sep 30, 2025-$43.09M–
Q2 FY2025Jun 30, 2025-$27.30M–
Q1 FY2025Mar 31, 2025$111.24M–
Q4 FY2024Dec 31, 2024-$13.65M–
Q3 FY2024Sep 30, 2024-$30.00M–
Q2 FY2024Jun 30, 2024-$29.34M–
Q1 FY2024Mar 31, 2024-$28.37M–
Q4 FY2023Dec 31, 2023-$29.59M–
Q3 FY2023Sep 30, 2023-$27.23M–
Q2 FY2023Jun 30, 2023-$33.26M–
Q1 FY2023Mar 31, 2023-$24.69M–
Q4 FY2022Dec 31, 2022-$27.18M–
Q3 FY2022Sep 30, 2022-$27.15M–
Q2 FY2022Jun 30, 2022-$25.24M–
Q1 FY2022Mar 31, 2022-$24.80M–
Q4 FY2021Dec 31, 2021-$24.53M–
Q3 FY2021Sep 30, 2021-$22.68M–
Q2 FY2021Jun 30, 2021-$22.03M–
Q1 FY2021Mar 31, 2021-$16.83M–
Q4 FY2020Dec 31, 2020-$14.59M–
Q3 FY2020Sep 30, 2020-$13.71M–
Q2 FY2020Jun 30, 2020-$13.01M–
Q1 FY2020Mar 31, 2020-$11.74M–
Q4 FY2019Dec 31, 2019-$11.07M–
Q3 FY2019Sep 30, 2019-$9.84M–
Q2 FY2019Jun 30, 2019-$8.45M–
Q1 FY2019Mar 31, 2019-$6.32M–
Q4 FY2018Dec 31, 2018-$4.54M–
Q3 FY2018Sep 30, 2018-$3.32M–
Q2 FY2018Jun 30, 2018-$3.01M–
Q1 FY2018Mar 31, 2018-$1.91M–

More Stoke Therapeutics figures

See a number that looks wrong?